Northeast GI Research Division(6.2 mi away)Contact
+65 other location
This is a Phase 2, multi-center, double-blind, randomized, placebo-controlled study to
evaluate the safety and efficacy on TVB-2640 in subjects with non-alcoholic steatohepatitis
(NASH). Subjects will be randomly assigned toTVB-2640 or matching placebo PO QD for 52 weeks,
with the first dose administered on Day 1.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.